Pages that link to "Q42224732"
Jump to navigation
Jump to search
The following pages link to Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. (Q42224732):
Displaying 43 items.
- Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update (Q28290363) (← links)
- Comparative molecular field analysis and QSAR on substrates binding to cytochrome p450 2D6. (Q30311976) (← links)
- The Use of In Vitro Data and Physiologically-Based Pharmacokinetic Modeling to Predict Drug Metabolite Exposure: Desipramine Exposure in Cytochrome P4502D6 Extensive and Poor Metabolizers Following Administration of Imipramine (Q31116232) (← links)
- Use of robust classification techniques for the prediction of human cytochrome P450 2D6 inhibition (Q31150072) (← links)
- Seizures associated with therapeutic doses of venlafaxine and trimipramine (Q31805799) (← links)
- Summary of information on human CYP enzymes: human P450 metabolism data (Q32103802) (← links)
- The influence of long-term treatment with psychotropic drugs on cytochrome P450: the involvement of different mechanisms (Q33254664) (← links)
- Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system (Q33630990) (← links)
- Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study (Q33634928) (← links)
- Inhibitory monoclonal antibodies to human cytochrome P450 enzymes: a new avenue for drug discovery (Q33763409) (← links)
- Influence of antidepressant drugs on chlorpromazine metabolism in human liver--an in vitro study (Q33805832) (← links)
- SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression (Q33884433) (← links)
- Coprescription of tamoxifen and medications that inhibit CYP2D6. (Q33898184) (← links)
- Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. (Q34331552) (← links)
- Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants (Q34650915) (← links)
- Pharmacogenetics of anxiolytic drugs. (Q34980499) (← links)
- Toxicological interactions involving psychiatric drugs and alcohol: an update (Q35114132) (← links)
- Depression in children and adolescents with epilepsy (Q35573303) (← links)
- Clinical Pharmacokinetics of Drugs Used to Treat Urge Incontinence (Q35579415) (← links)
- Concurrent administration of donepezil HCl and sertraline HCl in healthy volunteers: assessment of pharmacokinetic changes and safety following single and multiple oral doses (Q35826258) (← links)
- Aging and clinical pharmacology: implications for antidepressants (Q36261418) (← links)
- Treatment of anxiety disorders with venlafaxine XR. (Q36419538) (← links)
- Time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants (Q36535990) (← links)
- Antidepressant-drug interactions are potentially but rarely clinically significant (Q36538987) (← links)
- An open-label investigation of the pharmacokinetic profiles of lisdexamfetamine dimesylate and venlafaxine extended-release, administered alone and in combination, in healthy adults (Q36718468) (← links)
- Pre-clinical evaluation of CYP 2D6 dependent drug-drug interactions between primaquine and SSRI/SNRI antidepressants (Q36907360) (← links)
- Depression and anxiety in children and adolescents with epilepsy: prevalence, risk factors, and treatment. (Q37274178) (← links)
- Psychopharmacology in psychodermatology (Q37422575) (← links)
- Clinically significant drug interactions with newer antidepressants (Q37968621) (← links)
- The use of lisdexamfetamine dimesylate for the treatment of ADHD and other psychiatric disorders. (Q38221823) (← links)
- Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications (Q41756842) (← links)
- Factors that impact choice of antidepressant treatment in medically complex patients (Q43096808) (← links)
- Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes (Q43242688) (← links)
- Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe (Q43576840) (← links)
- Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. (Q44202468) (← links)
- High-throughput screening to estimate single or multiple enzymes involved in drug metabolism: microtitre plate assay using a combination of recombinant CYP2D6 and human liver microsomes (Q44560574) (← links)
- 'Open access' generic method for continuous determination of major human CYP450 probe substrates/metabolites and its application in drug metabolism studies (Q44741198) (← links)
- Development and Qualification of Physiologically Based Pharmacokinetic Models for Drugs With Atypical Distribution Behavior: A Desipramine Case Study. (Q46018689) (← links)
- Effect of venlafaxine on imipramine metabolism (Q46251633) (← links)
- Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study). (Q46850739) (← links)
- In vitro inhibition and induction of human cytochrome P450 enzymes by SIPI5357, a potential antidepressant (Q48095337) (← links)
- Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir (Q50984945) (← links)
- Symptomatic hypotension with venlafaxine-benzodiazepine interaction (Q88082340) (← links)